$23.40
+6.03 (+34.72%)
Open$17.74
Previous Close$17.37
Day High$24.00
Day Low$17.28
52W High$42.12
52W Low$3.66
Volume—
Avg Volume48.5K
Market Cap37.11M
P/E Ratio—
EPS$-18.93
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-47.1% upside
Current
$23.40
$23.40
Target
$12.39
$12.39
$7.78
$12.39 avg
$16.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.65M | 4.59M | 4.05M |
| Net Income | -16,276,055 | -196,564 | -196,089 |
| Profit Margin | -128.7% | -4.3% | -4.8% |
| EBITDA | -16,317,794 | -265,994 | -241,454 |
| Free Cash Flow | — | -252,687 | -239,821 |
| Rev Growth | — | +16.2% | +0.5% |
| Debt/Equity | 0.20 | 1.06 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |